Results 61 to 70 of about 97,904 (95)
Some of the next articles are maybe not open access.
Medical Journal of Australia, 1999
Antiplatelet drugs protect against myocardial infarction, stroke, cardiovascular death and other serious vascular events in patients with a history of previous vascular events or known risk factors for cardiovascular disease. Aspirin reduces the risk of serious vascular events in patients at high risk of such an event by about a quarter and is ...
R I, Baker, G J, Hankey
openaire +3 more sources
Antiplatelet drugs protect against myocardial infarction, stroke, cardiovascular death and other serious vascular events in patients with a history of previous vascular events or known risk factors for cardiovascular disease. Aspirin reduces the risk of serious vascular events in patients at high risk of such an event by about a quarter and is ...
R I, Baker, G J, Hankey
openaire +3 more sources
Hematology, 2009
Abstract The introduction of aspirin as an anti-thrombotic agent some 50 years ago has changed the therapeutic approach in cardiovascular medicine. Since platelets play a key role in the development of arterial thrombosis, antiplatelet drugs serve as a cornerstone in the prevention and the treatment of these conditions.
David, Varon, Galia, Spectre
openaire +2 more sources
Abstract The introduction of aspirin as an anti-thrombotic agent some 50 years ago has changed the therapeutic approach in cardiovascular medicine. Since platelets play a key role in the development of arterial thrombosis, antiplatelet drugs serve as a cornerstone in the prevention and the treatment of these conditions.
David, Varon, Galia, Spectre
openaire +2 more sources
The American Journal of Medicine, 1996
The major clinical indication for antiplatelet therapy has been the prevention of arterial thrombosis. Arterial thrombi are composed of predominantly platelets formed under conditions of elevated shear stress at sites of atherosclerotic vascular injury and disturbed blood flow.
openaire +2 more sources
The major clinical indication for antiplatelet therapy has been the prevention of arterial thrombosis. Arterial thrombi are composed of predominantly platelets formed under conditions of elevated shear stress at sites of atherosclerotic vascular injury and disturbed blood flow.
openaire +2 more sources
Australian and New Zealand Journal of Medicine, 1998
AbstractAspirin is an established therapy for the management of acute myocardial infarction (AMI) and unstable angina. Secondary prevention with chronic aspirin therapy is also indicated for patients with stable angina.Aspirin inhibits cyclo‐oxygenase‐I, a key enzyme in the biosynthetic pathway leading to the production of thromboxane A2.
H D, White, J K, French, C J, Ellis
openaire +2 more sources
AbstractAspirin is an established therapy for the management of acute myocardial infarction (AMI) and unstable angina. Secondary prevention with chronic aspirin therapy is also indicated for patients with stable angina.Aspirin inhibits cyclo‐oxygenase‐I, a key enzyme in the biosynthetic pathway leading to the production of thromboxane A2.
H D, White, J K, French, C J, Ellis
openaire +2 more sources
Hospital Medicine, 2000
Within the last few years antiplatelet therapy has developed exponentially, with new agents being tested in an increasing number of clinical scenarios. The mechanism of action of these newer agents and evidence of benefit is prevented in this review.
openaire +2 more sources
Within the last few years antiplatelet therapy has developed exponentially, with new agents being tested in an increasing number of clinical scenarios. The mechanism of action of these newer agents and evidence of benefit is prevented in this review.
openaire +2 more sources
Antiplatelet drug nonresponsiveness
American Heart Journal, 2008The response to most medication, including antiplatelet drugs, is highly variable between individuals. Observational studies have shown that nonresponders to antiplatelet agents appear to have an increased incidence of vascular events. This review article reviews the background, mechanisms, and evidence in support of the clinical significance of this ...
Patrick, Gladding +4 more
openaire +2 more sources
American Heart Journal, 2010
Antiplatelet therapy is a cornerstone of the management of patients with acute coronary syndromes or for those undergoing percutaneous coronary intervention. As the intricacies of platelet biology and mechanisms of thrombus formation are revealed, novel antiplatelet therapies have emerged.
Michael A, Gaglia +2 more
openaire +2 more sources
Antiplatelet therapy is a cornerstone of the management of patients with acute coronary syndromes or for those undergoing percutaneous coronary intervention. As the intricacies of platelet biology and mechanisms of thrombus formation are revealed, novel antiplatelet therapies have emerged.
Michael A, Gaglia +2 more
openaire +2 more sources
Antiplatelet therapy – ticagrelor
Hämostaseologie, 2012SummaryTicagrelor, a cyclopentyltriazolopyrimidine (CPTP), is the representative of a new chemical class of P2Y12 receptor inhibitors that differ from thienopyridines (ticlopidin, clopidogrel, prasugrel) as ticagrelor is not a prodrug requiring active biotransformation by cytochromes in the liver and thus is characterized by a more rapid, more ...
E, Giannitsis, H A, Katus
openaire +2 more sources
Current Opinion in Hematology, 2009
Cardiovascular events are still a major concern despite dual antiplatelet treatment with aspirin and clopidogrel. Moreover, recent developments that improved platelet inhibition were associated with increased bleeding complications, suggesting that personal dose adjustment might be needed.
Galia, Spectre, David, Varon
openaire +2 more sources
Cardiovascular events are still a major concern despite dual antiplatelet treatment with aspirin and clopidogrel. Moreover, recent developments that improved platelet inhibition were associated with increased bleeding complications, suggesting that personal dose adjustment might be needed.
Galia, Spectre, David, Varon
openaire +2 more sources
Monitoring Antiplatelet Therapy
Seminars in Thrombosis and Hemostasis, 2017The increasing use of antiplatelet therapy, particularly aspirin and oral P2Y12 inhibitors, in the prevention and management of arterial thrombosis, has stimulated extensive pharmacodynamic studies and research into tailored antiplatelet regimens. Many different methodologies have been studied for monitoring antiplatelet drugs and some are now well ...
Rachel, Orme +2 more
openaire +2 more sources